Vertex Signs LOI With The Pan-Canadian Pharmaceutical Alliance For PrALYFTREK For The Treatment Of Cystic Fibrosis In Patients Aged 6 Years And Older Who Have At Least One F508del Mutation Or Another Responsive Mutation In The CFTR Gene

뉴스 본문을 불러오고 있어요.

Vertex Signs LOI With The Pan-Canadian Pharmaceutical Alliance For PrALYFTREK For The Treatment Of Cystic Fibrosis In Patients Aged 6 Years And Older Who Have At Least One F508del Mutation Or Another Responsive Mutation In The CFTR Gene | 웨이프 WAPE

Vertex Signs LOI With The Pan-Canadian Pharmaceutical Alliance For PrALYFTREK For The Treatment Of Cystic Fibrosis In Patients Aged 6 Years And Older Who Have At Least One F508del Mutation Or Another Responsive Mutation In The CFTR Gene

기사 요약

관련 종목

댓글 —